{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:26:26Z","timestamp":1768807586488,"version":"3.49.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","award":["CDF 2014-07-045"],"award-info":[{"award-number":["CDF 2014-07-045"]}],"id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/14\/15\/30661"],"award-info":[{"award-number":["FS\/14\/15\/30661"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6134217"],"award-info":[{"award-number":["RE\/18\/6134217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48\u2009h intravenous infusion of serelaxin (30\u2009\u00b5g\/kg\/day) or matching placebo. The primary endpoints were change from baseline to 47\u2009h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47\u2009h, Day 30, and Day 180; aortic distensibility at 47\u2009h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n\u2009=\u200925; placebo, n\u2009=\u200926). After 2 and 6\u2009h of serelaxin infusion, mean placebo-corrected blood pressure reductions of \u22129.6\u2009mmHg (P\u2009=\u20090.01) and \u221213.5\u2009mmHg (P\u2009=\u20090.0003) for systolic blood pressure and \u22125.2\u2009mmHg (P\u2009=\u20090.02) and \u22128.4\u2009mmHg (P\u2009=\u20090.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47\u2009h in global MPR (\u22120.24 vs. \u22120.13, P\u2009=\u20090.44) or AIx (3.49% vs. 0.04%, P\u2009=\u20090.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, n\u2009=\u20095; placebo, n\u2009=\u20097) to 180-day follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with stable CAD, 48\u2009h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvz345","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T20:09:41Z","timestamp":1579723781000},"page":"320-329","source":"Crossref","is-referenced-by-count":7,"title":["Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5047-0885","authenticated-orcid":false,"given":"David","family":"Corcoran","sequence":"first","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK"},{"name":"Golden Jubilee National Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-6863","authenticated-orcid":false,"given":"Aleksandra","family":"Radjenovic","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-729X","authenticated-orcid":false,"given":"Ify R","family":"Mordi","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK"},{"name":"Golden Jubilee National Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheraz A","family":"Nazir","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J","family":"Wilson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-8342","authenticated-orcid":false,"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-515X","authenticated-orcid":false,"given":"Denise P","family":"Yates","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Machineni","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Private Limited, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Alcantara","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F","family":"Prescott","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-0803","authenticated-orcid":false,"given":"Barbara","family":"Gugliotta","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinuo","family":"Pang","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niko","family":"Tzemos","sequence":"additional","affiliation":[{"name":"London Health Science Centre, University of Western Ontario, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott I","family":"Semple","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4628","authenticated-orcid":false,"given":"David E","family":"Newby","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-8448","authenticated-orcid":false,"given":"Gerry P","family":"McCann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-8636","authenticated-orcid":false,"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK"},{"name":"Golden Jubilee National Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"2021011510043329400_cvz345-B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2021011510043329400_cvz345-B2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/17512433.2015.1073587","article-title":"Serelaxin a novel treatment for acute heart failure","volume":"8","author":"Castrini","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2021011510043329400_cvz345-B3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/er.2003-0013","article-title":"Relaxin's physiological roles and other diverse actions","volume":"25","author":"Sherwood","year":"2004","journal-title":"Endocr Rev"},{"key":"2021011510043329400_cvz345-B4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2007.09.008","article-title":"Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis","volume":"280","author":"Bathgate","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"2021011510043329400_cvz345-B5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J Card Fail"},{"key":"2021011510043329400_cvz345-B6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11897-010-0010-z","article-title":"Relaxin: review of biology and potential role in treating heart failure","volume":"7","author":"Teichman","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"2021011510043329400_cvz345-B7","first-page":"716","article-title":"Effects of serelaxin in patients with acute heart failure","volume-title":"N Engl J Med","year":"2019"},{"key":"2021011510043329400_cvz345-B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.106.623199","article-title":"Navigating the crossroads of coronary artery disease and heart failure","volume":"114","author":"Gheorghiade","year":"2006","journal-title":"Circulation"},{"key":"2021011510043329400_cvz345-B9","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"2021011510043329400_cvz345-B10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"2021011510043329400_cvz345-B11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jacc.2011.11.061","article-title":"Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow","volume":"59","author":"Ezekowitz","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2021011510043329400_cvz345-B12","doi-asserted-by":"crossref","first-page":"39604.","DOI":"10.1038\/srep39604","article-title":"Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes","volume":"7","author":"Ng","year":"2017","journal-title":"Sci Rep"},{"key":"2021011510043329400_cvz345-B13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/hc0202.102119","article-title":"Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction","volume":"105","author":"Neglia","year":"2002","journal-title":"Circulation"},{"key":"2021011510043329400_cvz345-B14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/eurheartj\/ehi795","article-title":"The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy","volume":"27","author":"Rigo","year":"2006","journal-title":"Eur Heart J"},{"key":"2021011510043329400_cvz345-B15","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.amjcard.2006.11.049","article-title":"The independent prognostic value of contractile and coronary flow reserve determined by dipyridamole stress echocardiography in patients with idiopathic dilated cardiomyopathy","volume":"99","author":"Rigo","year":"2007","journal-title":"Am J Cardiol"},{"key":"2021011510043329400_cvz345-B16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cardfail.2010.08.003","article-title":"Prognostic value of left and right coronary flow reserve assessment in nonischemic dilated cardiomyopathy by transthoracic Doppler echocardiography","volume":"17","author":"Rigo","year":"2011","journal-title":"J Card Fail"},{"key":"2021011510043329400_cvz345-B17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/ehjci\/jev012","article-title":"Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes","volume":"16","author":"Majmudar","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2021011510043329400_cvz345-B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1196\/annals.1282.064","article-title":"Human recombinant relaxin reduces heart injury and improves ventricular performance in a swine model of acute myocardial infarction","volume":"1041","author":"Perna","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2021011510043329400_cvz345-B19","first-page":"609","article-title":"Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism","volume":"113","author":"Valle Raleigh","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2021011510043329400_cvz345-B20","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jacc.2016.07.752","article-title":"Cardiac-coronary coupling","volume":"68","author":"Perera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021011510043329400_cvz345-B21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF01906680","article-title":"Model of the coronary circulation based on pressure dependence of coronary resistance and compliance","volume":"83","author":"Bruinsma","year":"1988","journal-title":"Basic Res Cardiol"},{"key":"2021011510043329400_cvz345-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2006.12.050","article-title":"Mechanical factors in arterial aging: a clinical perspective","volume":"50","author":"O'Rourke","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2021011510043329400_cvz345-B23","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1136\/hrt.2007.126128","article-title":"Possible link between large artery stiffness and coronary flow velocity reserve","volume":"94","author":"Saito","year":"2008","journal-title":"Heart"},{"key":"2021011510043329400_cvz345-B24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/eurheartj\/ehx001","article-title":"Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study","volume":"38","author":"Singh","year":"2017","journal-title":"Eur Heart J"},{"key":"2021011510043329400_cvz345-B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1118\/1.598163","article-title":"Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution","volume":"25","author":"Jerosch-Herold","year":"1998","journal-title":"Med Phys"},{"key":"2021011510043329400_cvz345-B26","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/mrm.22538","article-title":"Estimates of systolic and diastolic myocardial blood flow by dynamic contrast-enhanced MRI","volume":"64","author":"Radjenovic","year":"2010","journal-title":"Magn Reson Med"},{"key":"2021011510043329400_cvz345-B27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/hy1001.096106","article-title":"Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform","volume":"38","author":"Pauca","year":"2001","journal-title":"Hypertension"},{"key":"2021011510043329400_cvz345-B28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.amjhyper.2007.03.006","article-title":"Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure","volume":"20","author":"Adji","year":"2007","journal-title":"Am J Hypertens"},{"key":"2021011510043329400_cvz345-B29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.12572","article-title":"Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study","volume":"79","author":"Kobalava","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2021011510043329400_cvz345-B30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ejheart.2008.09.009","article-title":"Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)","volume":"10","author":"Rossi","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2021011510043329400_cvz345-B31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jcmg.2011.07.002","article-title":"Absolute myocardial blood flow emerging role in coronary pathophysiology and clinical disease","volume":"4","author":"Klocke","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2021011510043329400_cvz345-B32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mrm.24611","article-title":"Myocardial blood flow at rest and stress measured with dynamic contrast-enhanced MRI: comparison of a distributed parameter model with a Fermi function model","volume":"70","author":"Broadbent","year":"2013","journal-title":"Magn Reson Med"},{"key":"2021011510043329400_cvz345-B33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.14140433","article-title":"Comparison of the diagnostic performance of four quantitative myocardial perfusion estimation methods used in cardiac MR imaging: CE-MARC substudy","volume":"275","author":"Biglands","year":"2015","journal-title":"Radiology"},{"key":"2021011510043329400_cvz345-B34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/01.fjc.0000245404.20922.9f","article-title":"Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: a substudy of the persantine in stable angina (PISA) study","volume":"48","author":"Jagathesan","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"2021011510043329400_cvz345-B35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/01.CIR.57.4.732","article-title":"Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin","volume":"57","author":"Mann","year":"1978","journal-title":"Circulation"},{"key":"2021011510043329400_cvz345-B36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.109.886655","article-title":"Arterial stiffness and cardiovascular events: the Framingham Heart Study","volume":"121","author":"Mitchell","year":"2010","journal-title":"Circulation"},{"key":"2021011510043329400_cvz345-B37","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1161\/01.CIR.92.11.3212","article-title":"Endothelial control of arterial distensibility is impaired in chronic heart failure","volume":"92","author":"Ramsey","year":"1995","journal-title":"Circulation"},{"key":"2021011510043329400_cvz345-B38","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1152\/ajpregu.00635.2001","article-title":"Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats","volume":"283","author":"Novak","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2021011510043329400_cvz345-B39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/gut.49.4.577","article-title":"Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo","volume":"49","author":"Williams","year":"2001","journal-title":"Gut"},{"key":"2021011510043329400_cvz345-B40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.12247","article-title":"Relaxin decreases the severity of established hepatic fibrosis in mice","volume":"34","author":"Bennett","year":"2014","journal-title":"Liver Int"},{"key":"2021011510043329400_cvz345-B41","doi-asserted-by":"crossref","first-page":"H1609","DOI":"10.1152\/ajpheart.00360.2010","article-title":"Aging attenuates the vasodilator response to relaxin","volume":"300","author":"van Drongelen","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021011510043329400_cvz345-B42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10557-014-6525-x","article-title":"Diverse regulation of cardiac expression of relaxin receptor by \u03b11- and \u03b21-adrenoceptors","volume":"28","author":"Moore","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"2021011510043329400_cvz345-B43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardfail.2010.08.011","article-title":"The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling","volume":"17","author":"Dschietzig","year":"2011","journal-title":"J Card Fail"},{"key":"2021011510043329400_cvz345-B44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jcph.607","article-title":"Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: a single-dose, open-label, parallel-group study","volume":"56","author":"Dahlke","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2021011510043329400_cvz345-B45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.433","article-title":"Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations","volume":"55","author":"Dahlke","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2021011510043329400_cvz345-B46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":". Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2021011510043329400_cvz345-B47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.12964","article-title":"Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins","volume":"172","author":"Sarwar","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2021011510043329400_cvz345-B48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcin.2014.02.009","article-title":"Adenosine: physiology, pharmacology, and clinical applications","volume":"7","author":"Layland","year":"2014","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/117\/1\/320\/35878107\/cvz345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/117\/1\/320\/35878107\/cvz345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T15:05:50Z","timestamp":1610723150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/117\/1\/320\/5739335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,17]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz345","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,2,17]]}}}